litlas
ログインアカウント作成

Stefan Faderl

1991–2024 年に発表

177
論文数
35,117
被引用数
110
h 指数
175
i10 指数

被引用数

Stefan Faderl の年別被引用数1996 年: 被引用 1 件1997 年: 被引用 1 件1998 年: 被引用 1 件1999 年: 被引用 5 件2000 年: 被引用 26 件2001 年: 被引用 32 件2002 年: 被引用 66 件2003 年: 被引用 189 件2004 年: 被引用 192 件2005 年: 被引用 177 件2006 年: 被引用 292 件2007 年: 被引用 324 件2008 年: 被引用 335 件2009 年: 被引用 389 件2010 年: 被引用 344 件2011 年: 被引用 328 件2012 年: 被引用 354 件2013 年: 被引用 329 件2014 年: 被引用 325 件2015 年: 被引用 339 件2016 年: 被引用 315 件2017 年: 被引用 262 件2018 年: 被引用 274 件2019 年: 被引用 808 件2020 年: 被引用 790 件2021 年: 被引用 700 件2022 年: 被引用 415 件2023 年: 被引用 318 件2024 年: 被引用 462 件2025 年: 被引用 199 件2026 年: 被引用 1 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,071 件、この内訳の 31.3%ドイツ: 引用元論文 755 件、この内訳の 7.7%イタリア: 引用元論文 672 件、この内訳の 6.8%イギリス: 引用元論文 615 件、この内訳の 6.3%中国: 引用元論文 574 件、この内訳の 5.8%フランス: 引用元論文 509 件、この内訳の 5.2%スペイン: 引用元論文 309 件、この内訳の 3.2%カナダ: 引用元論文 269 件、この内訳の 2.7%オーストラリア: 引用元論文 259 件、この内訳の 2.6%オランダ: 引用元論文 231 件、この内訳の 2.4%スイス: 引用元論文 215 件、この内訳の 2.2%日本: 引用元論文 208 件、この内訳の 2.1%
0%31.3%その他 21.7%

機関

分野

  • Medicine73.9%
  • Biochemistry, Genetics and Molecular Biology20.6%
  • Immunology and Microbiology2.7%
  • Chemistry0.5%
  • Computer Science0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • その他1.4%

トピック

  • Acute Myeloid Leukemia Research11.8%
  • Chronic Myeloid Leukemia Treatments8%
  • Chronic Lymphocytic Leukemia Research6.9%
  • Acute Lymphoblastic Leukemia research6.3%
  • Lymphoma Diagnosis and Treatment3.9%
  • Histone Deacetylase Inhibitors Research3.4%
  • その他59.7%

共著者

全論文

検索で開く
  1. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    著者: Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur - Journal of Clinical Oncology 2012 被引用: 1,173

  2. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

    著者: Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Dale L. Bixby, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Daniel Ryan, Stefan Faderl, Jörge E. Cortes - The Lancet Haematology 2021 被引用: 211

  3. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

    著者: Yasmin Abaza, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Elihu H. Estey, Gautam Borthakur, Elias Jabbour, Stefan Faderl, Susan O’Brien, William G. Wierda, Sherry Pierce, Mark Brandt, Deborah McCue, Rajyalakshmi Luthra, Keyur P. Patel, Steven M. Kornblau, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Nitin Jain, Srđan Verstovšek, Alessandra Ferrajoli, Michael Andreeff, Marina Konopleva, Zeev Estrov, Maria Cielo Foudray, David McCue, Jörge E. Cortes, Farhad Ravandi - Blood 2016 被引用: 297

  4. Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

    著者: Farhad Ravandi, Susan O’Brien, Jörge E. Cortes, Deborah Thomas, Rebecca Garris, Stefan Faderl, Jan A. Burger, Michael Rytting, Alessandra Ferrajoli, William G. Wierda, Srđan Verstovšek, Richard E. Champlin, Partow Kebriaei, Deborah McCue, Xuelin Huang, Elias Jabbour, Guillermo Garcia‐Manero, Zeev Estrov, Hagop M. Kantarjian - Cancer 2015 被引用: 223

  5. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

    著者: Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen, Partow Kebriaei, Elias Jabbour, Michael Rytting, Sergernne York, Farhad Ravandi, Rebecca Garris, Monica Kwari, Stefan Faderl, Jörge E. Cortes, Richard E. Champlin, Susan O’Brien - Cancer 2013 被引用: 302

  6. Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    著者: Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jörge E. Cortes, Luis Fayad, Robert Tarnai, Sa A. Wang, Richard Champlin, Anjali S. Advani, Susan O’Brien - The Lancet Oncology 2012 被引用: 412

  7. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

    著者: Hagop Kantarjian, Farhad Ravandi, Susan O’Brien, Jörge E. Cortes, Stefan Faderl, Guillermo Garcia‐Manero, Elias Jabbour, William G. Wierda, Tapan M. Kadia, Sherry Pierce, Jianqin Shan, Michael A. Keating, Emil J. Freireich - Blood 2010 被引用: 399

  8. Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma

    著者: Yasmin Abaza, Hagop M. Kantarjian, Stefan Faderl, Elias Jabbour, Nitin Jain, Deborah A. Thomas, Tapan M. Kadia, Gautam Borthakur, Joseph D. Khoury, Jan A. Burger, William G. Wierda, Susan O’Brien, Marina Konopleva, Alessandra Ferrajoli, Partow Kebriaei, Bouthaina S. Dabaja, Steven M. Kornblau, Yesid Alvarado, Naval Daver, Naveen Pemmaraju, Prithviraj Bose, Philip A. Thompson, Hind Al Azzawi, Mary Ann Kelly, Rebecca Garris, Preetesh Jain, Guillermo Garcia‐Manero, Jörge E. Cortes, Farhad Ravandi - American Journal of Hematology 2017 被引用: 108

  9. The Biology of Chronic Myeloid Leukemia

    著者: Stefan Faderl, Moshe Talpaz, Zeev Estrov, Susan O’Brien, Razelle Kurzrock, Hagop M. Kantarjian - New England Journal of Medicine 1999 被引用: 1,311

  10. Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

    著者: Deborah A. Thomas, Susan O’Brien, Stefan Faderl, Guillermo Garcia‐Manero, Alessandra Ferrajoli, William G. Wierda, Farhad Ravandi, Srđan Verstovšek, Jeffrey L. Jorgensen, Carlos E. Bueso‐Ramos, Michael Andreeff, Sherry Pierce, Rebecca Garris, Michael J. Keating, Jörge E. Cortes, Hagop M. Kantarjian - Journal of Clinical Oncology 2010 被引用: 412

  11. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    著者: Hagop M. Kantarjian, Yasuhiro Oki, Guillermo Garcia‐Manero, Xuelin Huang, Susan O’Brien, Jörge E. Cortes, Stefan Faderl, Carlos E. Bueso‐Ramos, Farhad Ravandi, Zeev Estrov, Alessandra Ferrajoli, William G. Wierda, Jianqin Shan, Jan Davis, Francis J. Giles, Hussain I. Saba, Jean‐Pierre J. Issa - Blood 2006 被引用: 689

  12. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

    著者: Michael R. Savona, Olatoyosi Odenike, Philip C. Amrein, David P. Steensma, Amy E. DeZern, Laura C. Michaelis, Stefan Faderl, Wael A. Harb, Hagop M. Kantarjian, James N. Lowder, Aram Oganesian, Mohammad Azab, Guillermo Garcia‐Manero - The Lancet Haematology 2019 被引用: 120

  13. Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

    著者: Farhad Ravandi, E Estey, Dan Jones, Stefan Faderl, Susan O’Brien, Jackie Fiorentino, Sherry Pierce, Deborah Blamble, Zeev Estrov, William G. Wierda, Alessandra Ferrajoli, Srđan Verstovšek, Guillermo Garcia‐Manero, Jörge E. Cortes, Hagop M. Kantarjian - Journal of Clinical Oncology 2008 被引用: 376

  14. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

    著者: Susan O’Brien, Deborah A. Thomas, Farhad Ravandi, Stefan Faderl, Sherry Pierce, Hagop M. Kantarjian - Cancer 2008 被引用: 133

  15. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

    著者: Farhad Ravandi, Hagop M. Kantarjian, Stefan Faderl, Guillermo Garcia‐Manero, Susan O’Brien, Charles Koller, Sherry Pierce, Mark Brandt, Deborah D. Kennedy, Jörge E. Cortes, Miloslav Beran - Leukemia Research 2009 被引用: 124

  16. Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

    著者: Je‐Hwan Lee, Stefan Faderl, John M. Pagel, Chul Won Jung, Sung‐Soo Yoon, Animesh Pardanani, Pamela S. Becker, Howard Lee, Jeongeun Choi, Kyoung-June Lee, Min Kyoung Kim, Jörge E. Cortes - Blood Advances 2020 被引用: 65

  17. Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

    著者: Jörge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet, Thomas Prébet - Journal of Hematology & Oncology 2022 被引用: 36

  18. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

    著者: Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes, Francis J. Giles, Stefan Faderl, Elias Jabbour, Guillermo Garcia‐Manero, William G. Wierda, Sherry Pierce, Jianqin Shan, Elihu H. Estey - Cancer 2006 被引用: 607

  19. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

    著者: Guillermo Garcia‐Manero, Hui Yang, Carlos E. Bueso‐Ramos, Alessandra Ferrajoli, Jörge E. Cortes, William G. Wierda, Stefan Faderl, Charles Koller, Gail Morris, Gary L. Rosner, Andrey Loboda, Valeria R. Fantin, Sophia Randolph, James S. Hardwick, John F. Reilly, Cong Chen, Justin L. Ricker, J. Paul Secrist, Victoria M. Richon, Stanley R. Frankel, Hagop M. Kantarjian - Blood 2007 被引用: 461

  20. Adult acute lymphoblastic leukemia

    著者: Stefan Faderl, Susan O’Brien, Ching‐Hon Pui, Wendy Stock, Meir Wetzler, Dieter Hoelzer, Hagop M. Kantarjian - Cancer 2010 被引用: 289

  21. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

    著者: Elias Jabbour, Hagop M. Kantarjian, Farhad Ravandi, Deborah A. Thomas, Xuelin Huang, Stefan Faderl, Naveen Pemmaraju, Naval Daver, Guillermo Garcia‐Manero, Koji Sasaki, Jörge E. Cortes, Rebecca Garris, C. Cameron Yin, Joseph D. Khoury, Jeffrey L. Jorgensen, Zeev Estrov, Zachary S. Bohannan, Marina Konopleva, Tapan M. Kadia, Nitin Jain, Courtney D. DiNardo, William G. Wierda, Vicky Jeanis, Susan O’Brien - The Lancet Oncology 2015 被引用: 280

  22. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

    著者: Ravin J. Garg, Hagop M. Kantarjian, Susan O’Brien, Alfonso Quintás‐Cardama, Stefan Faderl, Zeev Estrov, Jörge E. Cortes - Blood 2009 被引用: 166

  23. WP1066 Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells

    著者: Alessandra Ferrajoli, Stefan Faderl, Quin Van, Patricia E. Koch, David Harris, Zhiming Liu, Inbal Hazan‐Halevy, Yongtao Wang, Hagop M. Kantarjian, Waldemar Priebe, Zeev Estrov - Cancer Research 2007 被引用: 128

  24. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

    著者: Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Stuart L. Goldberg, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet - Blood Advances 2022 被引用: 29